Botox in urology: A new treatment modality without limitations?

EAU Update Series

Volumn 2, Issue 4 SPEC.ISS., 2004, Pages 170-178

  Schurch, Brigitte ^a   Reitz, André ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Benign prostatic hyperplasia; Botulinum toxin; Chronic prostatic pain; Chronic urinary retention; Detrusor sphincter dyssynergia; Neurogenic bladder; Overactive bladder

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLACEBO; RESINIFERATOXIN;

ANALGESIA; ARTICLE; ASTHENIA; CHRONIC DISEASE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IMPOTENCE; LD 50; LIBIDO DISORDER; MICTURITION; NEUROGENIC BLADDER; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; PROSTATE HYPERTROPHY; SIDE EFFECT; SOMNOLENCE; SPHINCTEROTOMY; SPINAL CORD INJURY; URGE INCONTINENCE; URINE INCONTINENCE; URINE RETENTION; UROLOGIC SURGERY; VISUAL DISORDER; XEROSTOMIA;

EID: 10244243850     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euus.2004.09.004     Document Type: Article

References (68)

1. L.L. Simpson Molecular pharmacology of botulinum toxin and tetanus toxin Annu Rev Pharmacol Toxicol 26 1986 427-453
2. A. Brashear M.F. Lew D.D. Dykstra C.L. Comella S.A. Factor R.L. Rodnitzky et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- responsive cervical dystonia Neurology 53 7 1999 1439-1446
3. M.F. Brin A. Blitzer Botulinum toxin: Dangerous terminology errors J R Soc Med 86 8 1993 493-494
4. R.R. Sloop B.A. Cole R.O. Escutin Human response to botulinum toxin injection: Type B compared with type A Neurology 49 1 1997 189-194
5. K.R. Aoki Pharmacology and immunology of botulinum toxin serotypes J Neurol 248 Suppl 1 2001 3-10
6. L.L. Simpson The neuroparalytic and hemaglutinin activity of botulinum toxin InT Neuropoisons: their pathophysiological actions 1971 Plenum Press New York p. 303-24
7. J.A. Coffield R.V. Considine L.L. Simpson The site and mechanism of action of botulinum neurotoxin J. Jankovic M. Hallet Therapy with botulinum toxin 1994 Marcel Dekker New York p. 3-13
8. I. MacKenzie G. Burnstock J.O. Dolly The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission Neuroscience 7 4 1982 997-1006
9. J. Purkiss M. Welch S. Doward K. Forster Capsaicin-stimulated release of substance P from cultural dorsal root ganglion neurons: Involvement of two distinct mechanisms Biochem Pharmacol 59 2000 1403-1406
10. M.J. Welch J.R. Purkiss K.A. Foster Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins Toxicon 38 2000 245-258
11. H. Ishikawa Y. Mitsui T. Yoshitomi K. Mashimo S. Aoki K. Mukuno et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented iris sphincter and dilatator muscles Jpn J Ophalmol 44 2000 106-109
12. K. Alderson J.B. Holds R.L. Anderson Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm Neurology 41 11 1991 1800-1805
13. M.J. Printer S. Vanden Noven D. Muccio N. Wallace Axotomy-like changes in cat motorneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission J Neurosci 11 1991 657-666
14. D.D. Dykstra A.A. Sidi A.B. Scott J.M. Pagel G.D. Goldish Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients J Urol 139 5 1988 919-922
15. D.D. Dykstra A.A. Sidi Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study Arch Phys Med Rehabil 71 1 1990 24-26
16. B. Schurch D. Hauri B. Rodic A. Curt M. Meyer A.B. Rossier Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients J Urol 155 3 1996 1023
17. B. Schurch J. Hodler B. Rodic Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections J Neurol Neurosurg Psychiatry 63 4 1997 474-476
18. H. Petit L. Wiart E. Gaujard F. Le Breton J.M. Ferriere A. Lagueny et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease Spinal Cord 36 2 1998 91-94
19. P. Gallien S. Robineau M. Verin M.P. Le Bot B. Nicolas R. Brissot Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin Arch Phys Med Rehabil 79 6 1998 715-717
20. B. Schurch D.M. Schmid P. Knapp An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A Eur Neurol 6 Suppl 4 1999 S83-S89
21. M. de Seze H. Petit P. Gallien M.P. de Seze P.A. Joseph J.M. Mazaux et al. Botulinum a toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease Eur Urol 42 1 2002 56-62
22. M.W. Phelan M. Franks G.T. Somogyi T. Yokoyama M.O. Fraser J.P. Lavelle et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction J Urol 165 4 2001 1107-1110
23. H.C. Kuo Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction J Urol 170 5 2003 1908-1912
24. D.H. Zermann M. Ishigooka R. Doggweiler-Wiygul J. Schubert R.A. Schmidt The male chronic pelvic pain syndrome World J Urol 19 3 2001 173-179
25. D. Zermann M. Ishigooka J. Schubert R.A. Schmidt Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 38 4 2000 393-399
26. S.K. Jarvis J.A. Abbott M.B. Lenart A. Steensma T.G. Vancaillie Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles Aust N Z J Obstet Gynaecol 44 1 2004 46-50
27. J.E. Oesterling Benign prostatic hyperplasia. Medical and minimally invasive treatment options N Engl J Med 332 2 1995 99-109
28. G.M. Clifford R.D. Farmer Medical therapy for benign prostatic hyperplasia: A review of the literature Eur Urol 38 1 2000 2-19
29. J.J. de la Rosette G. Alivizatos S. Madersbacher M. Perachino D. Thomas F. Desgrandchamps EAU Guidelines on benign prostatic hyperplasia (BPH) Eur Urol 40 3 2001 256-263
30. J.D. McConnell M.J. Barry R.C. Bruskewitz Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research Clin Pract Guidel Quick Ref Guide Clin 8 1994 1-17
31. P. Boyle C. Robertson R. Manski R.J. Padley C.G. Roehrborn Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia Urology 58 5 2001 717-722
32. H. Lepor W.O. Williford M.J. Barry M.K. Brawer C.M. Dixon G. Gormley et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group N Engl J Med 335 8 1996 533-539
33. P. Narayan H. Lepor Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia Urology 57 3 2001 466-470
34. R. Doggweiler D.H. Zermann M. Ishigooka R.A. Schmidt Botox-induced prostatic involution Prostate 37 1 1998 44-50
35. G. Maria G. Brisinda I.M. Civello A.R. Bentivoglio G. Sganga A. Albanese Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study Urology 62 2 2003 259-264
36. P. Abrams G. Larsson C. Chapple A.J. Wein Factors involved in the success of antimuscarinic treatment BJU Int 183 Suppl 2 1999 42-47
37. P. Abrams R. Freeman C. Anderstrom A. Mattiasson Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 6 1998 801-810
38. H.P. Drutz R.A. Appell D. Gleason I. Klimberg S. Radomski Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 10 5 1999 283-289
39. R.A. Appell Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis Urology 50 6A Suppl 1997 90-96
40. K. Kreder C. Mayne U. Jonas Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder Eur Urol 41 6 2002 588-595
41. I.M. Thompson R. Lauvetz Oxybutynin in bladder spasm, neurogenic bladder, and enuresis Urology 8 5 1976 452-454
42. S. Plevnik J. Janez Maximal electrical stimulation for urinary incontinence: Report of 98 cases Urology 14 6 1979 638-645
43. G.S. Brindley The first 500 patients with sacral anterior root stimulator implants: General description Paraplegia 32 12 1994 795-805
44. R.A. Schmidt Applications of neurostimulation in urology Neurourol Urodyn 7 1998 585-589
45. C.J. Fowler R.O. Beck S. Gerrard C.D. Betts C.G. Fowler Intravesical capsaicin for treatment of detrusor hyperreflexia J Neurol Neurosurg Psychiatry 57 2 1994 169-173
46. F. Cruz M. Guimaraes C. Silva M. Reis Suppression of bladder hyperreflexia by intravesical resiniferatoxin Lancet 350 9078 1997 640-641
47. B. Schurch D.M. Schmid M. Stohrer Treatment of neurogenic incontinence with botulinum toxin A N Engl J Med 342 9 2000 665
48. B. Schurch M. Stohrer G. Kramer D.M. Schmid G. Gaul D. Hauri Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results J Urol 164 3 Pt 1 2000 692-697
49. E.C. Dickson R. Shevky Studies on manner in which the toxin of clostridium botulinum acts upon the body. I. The effect upon the autonomic nervous system J Exp Med 37 1923 711-731
50. V. Annese M. Basciani O. Borrelli G. Leandro P. Simone A. Andriulli Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia Muscle Nerve 21 11 1998 1540-1542
51. M. Naumann P. Flachenecker E.B. Brocker K.V. Toyka K. Reiners Botulinum toxin for palmar hyperhidrosis Lancet 349 9047 1997 252
52. M. Naumann M. Zellner K.V. Toyka K. Reiners Treatment of gustatory sweating with botulinum toxin Ann Neurol 42 6 1997 973-975
53. F.G. Carpenter Motor responses of the response of the urinary bladder and skeletal muscle in botulinum toxin intoxicated rats J Physiol 1988 1967 1-11
54. A. Reitz M. Stohrer G. Kramer G. Del Popolo E. Chartier-Kastler J. Pannek et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity Eur Urol 45 4 2004 510-515
55. H. Schulte-Baukloh T. Michael J. Schobert T. Stolze H.H. Knispel Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: Preliminary results Urology 59 3 2002 325-327
56. H. Schulte-Baukloh T. Michael B. Sturzebecher H.H. Knispel Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder Eur Urol 44 1 2003 139-143
57. M. Riccabona M. Koen M. Schindler B. Goedele A. Pycha L. Lusuardi et al. Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia J Urol 171 2 Pt 1 2004 845-848
58. A. Loch T. Loch A. Osterhage S. Alloussi M. Stöckle Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence Eur Urol Suppl 2 1 2003 172
59. P. Radziszewski A. Borkowski Botulinum toxin type A intravesical injections for instable bladder overactivity Eur Urol Suppl 1 1 2002 134
60. D.M. Schmid B. Schurch H. John D. Hauri Botulinum toxin injections to treat overactvie bladder Eur Urol Suppl 3 2 2004 131
61. D.D. Dykstra J. Pryor G. Goldish Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: A case report Arch Phys Med Rehabil 84 9 2003 1399-1400
62. D. Dykstra A. Enriquez M. Valley Treatment of overactive bladder with botulinum toxin type B: A pilot study Int Urogynecol J Pelvic Floor Dysfunct 14 6 2003 424-426
63. A. Reitz B. Schurch Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity J Urol 171 2 Pt 1 2004 804
64. D. Pistolesi C. Selli B. Rossi G. Stampacchia Botulinum toxin type B for type A resistant bladder spasticity J Urol 171 2 Pt 1 2004 802-803
65. K.R. Kessler R. Benecke The EBD test- aclinical test for the detection of antibodies to botulinum type A Mov Disord 12 9 1997 95-99
66. K.R. Aoki A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice Toxicon 39 12 2001 1815-1820
67. S.L. Matarasso Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides Dermatol Surg 29 1 2003 7-13
68. R.M. Siatkowski A. Tyutyunikov A.W. Biglan D. Scalise C. Genovese R.B. et al. Raikow Serum antibody production to botulinum A toxin Ophthalmology 100 12 1993 1861-1866